Hearing Summary Report

Note: *Upload completed document to the Electronic Rule Filing System.*

Today's Date: .6/13/24

Hearing Date: 6 / 1 3 / 2 4

Agency: Ohio Bureau of Workers' Compensation

Rule Number(s): 4123-6-21.2, 4123-6-21.3, 4123-6-16.2

If no comments at the hearing, please check the box. ☐

In-Person Comments: No comments received.

Individual(s)/Organization(s)	Rule	Comments

Written Comments:

Individual(s)/Organization(s)	Rule	Comments
Amanda Rumpke, Ohio Association of Advanced Practice Nurses (OAAPRN)	4123-6-21.2	Request the introduction and Section (A) of the rule be amended to include nurse practitioners and clinical nurse specialists as providers eligible to be members of the pharmacy and therapeutics (P&T) committee
Michael Mathy, Ohio Physical Therapy Association (OPTA)	4123-6-21.3	Request certain forms of dexamethasone not be removed from the formulary and allow all variants to continue to be an option for prescribers working with injured workers.

Consolidated Summary of Comments Received

Please review all comments received and complete a consolidated summary paragraph of the comments and indicate the rule number(s).

See comments received above.

Hearing Summary Report

Incorporated Comments into Rule(s)

Indicate how comments received during the hearing process were incorporated into the rule(s). If no comments were incorporated, explain why not.

Comment Received	Rule	How Incorporated
OAAPRN	4123-6-21.2	Not incorporated. . After review of the feedback, BWC staff has determined not to add nurse practitioners and clinical nurse specialists to the Pharmacy & Therapeutics committee at this time. While these individuals can prescribe medications, they may do so only in collaboration with one or more physicians. The P&T committee reviews issues specific to prescribing; therefore, the current committee requirement for physician is considered a "peer-to-peer" review.
OPTA	4123-6-21.3	Not incorporated. After review of the feedback, BWC staff has concluded that the OPTA's request is a substantive change from the formulary appendix to rule OAC 4123-6-21.3 as presented to and approved by BWC's Board of Directors, and as such should be presented to the Board for consideration before such change could be made. Since there is insufficient time for BWC to do that and maintain our scheduled timeline of August 1, 2024 for the other formulary appendix updates, BWC plans to move forward with the currently proposed appendix. However, we will review the OPTA's request with our Pharmacy & Therapeutics Committee and consider reinstating the injectable corticosteroids to the formulary as part of our next scheduled formulary update to be taken to the BWC Board, which would be effective February 1, 2025.